Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
ProShares Ultra Nasdaq Biotechnology (BIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BIB (1-star) is a SELL. SELL since 5 days. Profits (-12.98%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type ETF | Historic Profit -42.25% | Avg. Invested days 36 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Volume (30-day avg) 7121 | Beta 1.33 | 52 Weeks Range 45.48 - 68.69 | Updated Date 04/2/2025 |
52 Weeks Range 45.48 - 68.69 | Updated Date 04/2/2025 |
Upturn AI SWOT
ProShares Ultra Nasdaq Biotechnology
ETF Overview
Overview
ProShares Ultra Nasdaq Biotechnology (BIB) is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index.
Reputation and Reliability
ProShares is a well-known issuer of leveraged and inverse ETFs, known for its expertise in this area.
Management Expertise
ProShares' management team has experience in creating and managing leveraged and inverse investment products.
Investment Objective
Goal
The ETF aims to provide twice the daily return of the Nasdaq Biotechnology Index.
Investment Approach and Strategy
Strategy: Leveraged ETF that seeks to deliver 2x the daily performance of the Nasdaq Biotechnology Index.
Composition The ETF uses financial instruments such as swap agreements to achieve its leveraged exposure. It does not directly hold stocks in the Nasdaq Biotechnology Index.
Market Position
Market Share: BIB's market share is a portion of the broader leveraged biotech ETF market, and fluctuates based on AUM and trading volume.
Total Net Assets (AUM): 275900000
Competitors
Key Competitors
- LABU
- BIS
- XBI
- IBB
Competitive Landscape
The leveraged ETF market is competitive. BIB offers 2x leverage compared to LABU's 3x, and both are leveraged plays on the same sector. Non-leveraged funds like IBB and XBI also compete for investor dollars interested in biotechnology.
Financial Performance
Historical Performance: Historical performance is dependent on the Nasdaq Biotechnology Index's performance and is amplified due to the 2x leverage. Past performance is not indicative of future results.
Benchmark Comparison: The ETF's performance aims to be 2x the daily return of the Nasdaq Biotechnology Index. Deviations may occur due to fees, expenses, and compounding effects.
Expense Ratio: 0.95
Liquidity
Average Trading Volume
Average trading volume fluctuates but is generally high, indicating good liquidity.
Bid-Ask Spread
The bid-ask spread is generally tight, but can widen during periods of high volatility.
Market Dynamics
Market Environment Factors
The ETF's performance is heavily influenced by biotechnology sector performance, regulatory changes, drug approvals, and overall market sentiment.
Growth Trajectory
Growth trajectory depends on biotechnology industry advancements, investor sentiment, and the ETF's ability to track its stated objective with leverage.
Moat and Competitive Advantages
Competitive Edge
BIB's advantage lies in offering a leveraged play on the Nasdaq Biotechnology Index, appealing to investors seeking amplified returns. Its focus allows investors to capitalize on short-term movements, while potentially enhancing returns in rapidly growing biotech market. However, investors must comprehend the risks associated with leveraged exposure, including increased volatility. The leverage factor allows it to stands out in market. BIBu2019s expense ratio also remains competitive compared to other leveraged biotech ETFs.
Risk Analysis
Volatility
Due to the 2x leverage, BIB exhibits high volatility.
Market Risk
The ETF is subject to market risk associated with the biotechnology sector, as well as the risks of leveraged investing including daily resets and compounding issues.
Investor Profile
Ideal Investor Profile
The ideal investor is sophisticated, has a high-risk tolerance, and seeks short-term gains from the biotechnology sector.
Market Risk
BIB is best suited for active traders with a short-term investment horizon and a thorough understanding of leveraged ETFs.
Summary
ProShares Ultra Nasdaq Biotechnology (BIB) is a leveraged ETF designed for short-term tactical exposure to the biotechnology sector. It aims to deliver twice the daily performance of the Nasdaq Biotechnology Index, making it a tool for experienced traders looking for amplified returns. However, the leverage creates high volatility and is not appropriate for long-term investors. Its suitability is restricted to investors with a high-risk tolerance and understanding of leveraged investment products and the biotechnology industry and they should monitor their positions closely and regularly.
Similar Companies
BIS
ProShares UltraShort Nasdaq Biotechnology
BIS
ProShares UltraShort Nasdaq Biotechnology
IBB
iShares Biotechnology ETF
IBB
iShares Biotechnology ETF
LABU
Direxion Daily S&P Biotech Bull 3X Shares
LABU
Direxion Daily S&P Biotech Bull 3X Shares
XBI
SPDR® S&P Biotech ETF
XBI
SPDR® S&P Biotech ETF
Sources and Disclaimers
Data Sources:
- ProShares website
- ETF.com
- Morningstar
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Leveraged ETFs are complex instruments and should be used with caution.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProShares Ultra Nasdaq Biotechnology
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.